-
公开(公告)号：US20050014226A1
公开(公告)日：2005-01-20
申请号：US10918851
申请日：2004-08-13
Applicant: Avi Ashkenazi , Kevin Baker , David Botstein , Luc Desnoyers , Dan Eaton , Napoleone Ferrara , Ellen Filvaroff , Sherman Fong , Wei-Oiang Gao , Hanspeter Gerber , Mary Gerritsen , Audrey Goddard , Paul Godowski , J. Grimaldi , Austin Gurney , Kenneth Hillan , Ivar Kljavin , Sophia Kuo , Mary Napier , James Pan , Nicholas Paoni , Margaret Roy , David Shelton , Timothy Stewart , Daniel Tumas , P. Williams , William Wood
Inventor： Avi Ashkenazi , Kevin Baker , David Botstein , Luc Desnoyers , Dan Eaton , Napoleone Ferrara , Ellen Filvaroff , Sherman Fong , Wei-Oiang Gao , Hanspeter Gerber , Mary Gerritsen , Audrey Goddard , Paul Godowski , J. Grimaldi , Austin Gurney , Kenneth Hillan , Ivar Kljavin , Sophia Kuo , Mary Napier , James Pan , Nicholas Paoni , Margaret Roy , David Shelton , Timothy Stewart , Daniel Tumas , P. Williams , William Wood
IPC: C07K14/47 , C07K14/705 , C07K16/18 , C07H21/04 , C12N9/00
CPC classification number: C07K16/18 , C07K14/47 , C07K14/4703 , C07K14/705 , C07K2319/00 , C07K2319/30 , C12N2799/026
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
-
82.发明申请公开(公告)号：US20050014225A1
公开(公告)日：2005-01-20
申请号：US10858981
申请日：2004-06-01
Applicant: David Botstein , Audrey Goddard , Paul Godowski , J. Grimaldi , Austin Gurney , Margaret Roy , William Wood
Inventor： David Botstein , Audrey Goddard , Paul Godowski , J. Grimaldi , Austin Gurney , Margaret Roy , William Wood
CPC classification number: C07K14/47 , A61K38/1709
Abstract: The present invention is directed to secreted and transmembrane polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Abstract translation: 本发明涉及分泌和跨膜多肽以及编码这些多肽的核酸分子。 本文还提供了包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的本发明的多肽的嵌合多肽分子，与本发明的多肽结合的抗体以及本发明的多肽的制备方法 发明。
-
公开(公告)号：US5770426A
公开(公告)日：1998-06-23
申请号：US660986
申请日：1996-06-12
Applicant: Stephen Anderson , William F. Bennett , David Botstein , Deborah L. Higgins , Nicholas F. Paoni , Mark J. Zoller
Inventor： Stephen Anderson , William F. Bennett , David Botstein , Deborah L. Higgins , Nicholas F. Paoni , Mark J. Zoller
IPC: A61K38/00 , A61K38/48 , C07H21/04 , C12N1/21 , C12N5/10 , C12N9/64 , C12N9/72 , C12N15/55 , C12N15/58 , C12N15/63 , C12N15/70 , C12N15/86
CPC classification number: C12N9/6456 , A61K38/00
Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.
-
公开(公告)号：US5714145A
公开(公告)日：1998-02-03
申请号：US733353
申请日：1996-10-17
Applicant: Stephen Anderson , William F. Bennett , David Botstein , Deborah L. Higgins , Nicholas F. Paoni , Mark J. Zoller
Inventor： Stephen Anderson , William F. Bennett , David Botstein , Deborah L. Higgins , Nicholas F. Paoni , Mark J. Zoller
Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.
-
公开(公告)号：US5616486A
公开(公告)日：1997-04-01
申请号：US422736
申请日：1995-04-14
Applicant: Stephen Anderson , William F. Bennett , David Botstein , Deborah L. Higgins , Nicholas F. Paoni , Mark J. Zoller
Inventor： Stephen Anderson , William F. Bennett , David Botstein , Deborah L. Higgins , Nicholas F. Paoni , Mark J. Zoller
IPC: A61K38/00 , A61K38/48 , C07H21/04 , C12N1/21 , C12N5/10 , C12N9/64 , C12N9/72 , C12N15/55 , C12N15/58 , C12N15/63 , C12N15/70 , C12N15/86
CPC classification number: C12N9/6456 , A61K38/00
Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.
-
Patent Agency Ranking86.发明授权Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells 失效具有酶原或纤维蛋白特异性的组织纤溶酶原激活剂在氨基酸位置296-299处被取代，编码它们的DNA分子，载体和宿主细胞
公开(公告)号：US5262170A
公开(公告)日：1993-11-16
申请号：US770510
申请日：1991-10-03
Applicant: Stephen Anderson , William F. Bennett , David Botstein , Deborah L. Higgins , Nicholas F. Paoni , Mark J. Zoller
Inventor： Stephen Anderson , William F. Bennett , David Botstein , Deborah L. Higgins , Nicholas F. Paoni , Mark J. Zoller
IPC: A61K38/00 , A61K38/48 , C07H21/04 , C12N1/21 , C12N5/10 , C12N9/64 , C12N9/72 , C12N15/55 , C12N15/58 , C12N15/63 , C12N15/70 , C12N15/86 , A61K37/547
CPC classification number: C12N9/6456 , A61K38/00
Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.
Abstract translation: 制备组织纤溶酶原激活剂（t-PA）酶原和变体，包括t-PA的纤维蛋白溶解活性变体，其在t-PA的蛋白酶结构域内的位置具有氨基酸改变，与相应的野生型t- PA，与相应的野生型t-PA相比，其改变使纤维蛋白溶酶原纤维蛋白原和/或纤维蛋白（或血浆凝块）存在下的变形酶原。 可以制备编码酶原和变体的DNA序列，以及掺入DNA序列的表达载体和用表达载体转化的宿主细胞。 酶原和变体可用于药物制剂中以治疗血管疾病或病症或预防纤维蛋白沉积或哺乳动物中的粘附形成或重新形成。
-
公开(公告)号：US08350008B2
公开(公告)日：2013-01-08
申请号：US13117051
申请日：2011-05-26
Applicant: David Botstein , Robert L. Cohen , Audrey D. Goddard , Austin L. Gurney , Kenneth J. Hillan , David A. Lawrence , Arnold J. Levine , Diane Pennica , Margaret Ann Roy , William I. Wood
Inventor： David Botstein , Robert L. Cohen , Audrey D. Goddard , Austin L. Gurney , Kenneth J. Hillan , David A. Lawrence , Arnold J. Levine , Diane Pennica , Margaret Ann Roy , William I. Wood
CPC classification number: C07K14/47 , C07K14/475 , C07K16/18 , C07K16/22 , C07K16/30 , C07K16/32 , C07K2317/73 , C07K2317/74 , C12Q1/6886 , C12Q2600/136
Abstract: Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.
-
公开(公告)号：US20110311540A1
公开(公告)日：2011-12-22
申请号：US13117051
申请日：2011-05-26
Applicant: David Botstein , Robert L. Cohen , Audrey D. Goddard , Austin L. Gurney , Kenneth J. Hillan , David A. Lawrence , Arnold J. Levine , Diane Pennica , Margaret Ann Roy , William I. Wood
Inventor： David Botstein , Robert L. Cohen , Audrey D. Goddard , Austin L. Gurney , Kenneth J. Hillan , David A. Lawrence , Arnold J. Levine , Diane Pennica , Margaret Ann Roy , William I. Wood
IPC: A61K39/395 , C07K16/46 , A61P35/00 , C07K16/22
CPC classification number: C07K14/47 , C07K14/475 , C07K16/18 , C07K16/22 , C07K16/30 , C07K16/32 , C07K2317/73 , C07K2317/74 , C12Q1/6886 , C12Q2600/136
Abstract: Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.
Abstract translation: 提供了Wnt-1诱导的分泌蛋白（WISP），其基因至少被Wnt-1诱导。 还提供了编码那些多肽的核酸分子，以及包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的多肽的嵌合多肽分子，与多肽结合的抗体，以及用于产生多肽的方法。
-
公开(公告)号：US20100221249A1
公开(公告)日：2010-09-02
申请号：US12648425
申请日：2009-12-29
Applicant: DAVID BOTSTEIN , ROBERT L. COHEN , AUDREY D. GODDARD , AUSTIN L. GURNEY , KENNETH J. HILLAN , DAVID A. LAWRENCE , ARNOLD J. LEVINE , DIANE PENNICA , MARGARET ANN ROY , WILLIAM I. WOOD
Inventor： DAVID BOTSTEIN , ROBERT L. COHEN , AUDREY D. GODDARD , AUSTIN L. GURNEY , KENNETH J. HILLAN , DAVID A. LAWRENCE , ARNOLD J. LEVINE , DIANE PENNICA , MARGARET ANN ROY , WILLIAM I. WOOD
IPC: A61K39/395 , A61P35/00
CPC classification number: C07K14/47 , C07K14/475 , C07K16/18 , C07K16/22 , C07K16/30 , C07K16/32 , C07K2317/73 , C07K2317/74 , C12Q1/6886 , C12Q2600/136
Abstract: Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.
Abstract translation: 提供了Wnt-1诱导的分泌蛋白（WISP），其基因至少被Wnt-1诱导。 还提供了编码那些多肽的核酸分子，以及包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的多肽的嵌合多肽分子，与多肽结合的抗体，以及用于产生多肽的方法。
-
90.发明申请Classification of Patients Having Diffuse Large B-cell Lymphoma Based upon Gene Expression 审中-公开基于基因表达的弥漫性大B细胞淋巴瘤患者分类公开(公告)号：US20100143926A1
公开(公告)日：2010-06-10
申请号：US12625523
申请日：2009-11-24
Applicant: Ronald Levy , Mark A. Wechser , Izidore S. Lossos , Robert J. Tibshirani , Ash A. Alizadeh , David Botstein
Inventor： Ronald Levy , Mark A. Wechser , Izidore S. Lossos , Robert J. Tibshirani , Ash A. Alizadeh , David Botstein
IPC: C12Q1/68
CPC classification number: G01N33/57426 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/16
Abstract: Methods and kits for classifying patients having diffuse large B-cell lymphoma (DLBCL) based upon expression of a plurality of genes are disclosed. Real-time quantitative RT-PCR can be used to measure expression values. Correlating expression values of the plurality of genes in a tumor sample from the patient to reference expression values obtained from DLBCL patients can stratify patients in the classification groups. The methods and kits can be used to predict overall patient survival.
Abstract translation: 公开了基于多个基因的表达来分类具有弥漫性大B细胞淋巴瘤（DLBCL）的患者的方法和试剂盒。 实时定量RT-PCR可用于测量表达值。 将来自患者的肿瘤样品中的多个基因的表达值与从DLBCL患者获得的参照表达值相关联可以对分类组中的患者进行分层。 方法和试剂盒可用于预测总体患者生存。
-
-
-
-
-
-
-
-
-
Search Results
109
records
(took 0.044 seconds)
